Posttransplant Metabolic Syndrome in the Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients (WISP‐R) Pilot Trial

Posttransplant metabolic syndrome (PTMS)—obesity, hypertension, elevated triglycerides, low HDL and glucose intolerance—is a major contributor to morbidity after adult liver transplant. This analysis of the Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients (WISP‐R) pilot trial is the first prospective study of PTMS after pediatric liver transplant. Twenty children were enrolled in WISP‐R, at median age 8.5 years (IQR 6.4–10.8), and weaned from calcineurin‐inhibitor monotherapy. The 12 children who tolerated complete immunosuppression withdrawal were compared to matched historical controls. At baseline, 45% of WISP‐R subjects and 58% of controls had at least one component of PTMS. Calcineurin‐inhibitor withdrawal in the WISP‐R subjects did not impact the prevalence of PTMS components compared to controls. At 5 years, despite weaning off of immunosuppression, 92% of the 12 tolerant WISP‐R subjects had at least one PTMS component and 58% had at least two; 33% were overweight or obese, 50% had dyslipidemia, 33% glucose intolerance and 42% systolic hypertension. Overweight/obesity increased the risk of hypertension in all children. Compared to controls, WISP‐R tolerant subjects had similar GFR at baseline but did have higher GFR at 2, 3 and 4 years. Further study of PTMS and immunosuppression withdrawal after pediatric liver transplant is warranted.

[1]  D. Simons-Morton,et al.  Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2016, Pediatric Clinical Practice Guidelines & Policies.

[2]  D. Roelen,et al.  Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients , 2013, Hepatology.

[3]  G. Tiao,et al.  The SPLIT Research Agenda 2013 , 2013, Pediatric transplantation.

[4]  P. Rosenthal,et al.  Posttransplant metabolic syndrome in children and adolescents after liver transplantation: A systematic review , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  R. Zietse,et al.  Pathogenesis of calcineurin inhibitor-induced hypertension. , 2012, Journal of nephrology.

[6]  A. Chan,et al.  Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. , 2012, The Cochrane database of systematic reviews.

[7]  D. Glidden,et al.  Overweight and obesity in pediatric liver transplant recipients: Prevalence and predictors before and after transplant, United Network for Organ Sharing Data, 1987–2010 , 2012, Pediatric transplantation.

[8]  K. Flegal,et al.  Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. , 2012, JAMA.

[9]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[10]  P. Rosenthal,et al.  Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. , 2012, JAMA.

[11]  D. Simons-Morton,et al.  Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2011, Pediatrics.

[12]  K. Watt.  Metabolic syndrome: Is immunosuppression to blame? , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  J. Sulkes,et al.  Metabolic syndrome in liver transplant recipients: Prevalence, risk factors, and association with cardiovascular events , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  L. Rubbia‐Brandt,et al.  Non-Alcoholic Fatty Liver Disease in Liver Transplant Recipients: Another Story of “Seed and Soil” , 2010, American Journal of Gastroenterology.

[15]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[16]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[17]  P. Parrilla,et al.  Immunosuppression withdrawal improves long‐term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients , 2009, Clinical transplantation.

[18]  F. Greenway,et al.  Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001-2006. , 2009, Archives of pediatrics & adolescent medicine.

[19]  Susan L Furth,et al.  New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[20]  S. Feng.  Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both? , 2008, Current opinion in organ transplantation.

[21]  E. Ford,et al.  Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. , 2008, The Journal of pediatrics.

[22]  S. Barlow,et al.  Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. , 2007, Pediatrics.

[23]  J. Sorof,et al.  Prevalence of hypertension and pre-hypertension among adolescents. , 2007, The Journal of pediatrics.

[24]  G. Mazariegos,et al.  Clinical tolerance following liver transplantation: long term results and future prospects. , 2007, Transplant immunology.

[25]  G. Iaria,et al.  Switch to 1.5 grams MMF monotherapy for CNI‐related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  G. Duncan.  Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. , 2006, Archives of pediatrics & adolescent medicine.

[27]  M. Christiaans,et al.  Evaluating mechanisms of post-transplant diabetes mellitus. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  B. Rosner,et al.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents , 2004 .

[29]  National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents , 2004, Pediatrics.

[30]  D. Lai,et al.  Overweight, ethnicity, and the prevalence of hypertension in school-aged children. , 2004, Pediatrics.

[31]  Shumei S. Guo,et al.  2000 CDC Growth Charts for the United States: methods and development. , 2002, Vital and health statistics. Series 11, Data from the National Health Survey.

[32]  Atlanta,et al.  Prevalence of abnormal lipid levels among youths --- United States, 1999-2006. , 2010, MMWR. Morbidity and mortality weekly report.

[33]  P. Yoon,et al.  Prevalence of abnormal lipid levels among youths --- United States, 1999-2006. , 2010, MMWR. Morbidity and mortality weekly report.

[34]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.